Diabetes results
June 14, 2012
THE results of the Evaluation of
Insulin Glargine Versus Sitagliptin in
Insulin-Naïve Patients study (EASIE)
showed that metformin achieved
superior glycemic control versus
sitagliptin in type 2 diabetes.
The EASIE research was a
multicenter, international,
randomised, open-label, six-month
study that compared once-daily
insulin glargine with sitagliptin (100
mg) once daily, as add-on therapy
to metformin, in insulin-naïve
people with early type 2 diabetes
(median disease duration after
diagnosis: 4.5 years).
According to the study’s findings
people with type 2 diabetes, who
were inadequately controlled by
metformin once-daily, insulin
glargine produced superior HbA1c
reduction (-1.7%) versus once daily
sitagliptin (-1.1%; p Interestingly researchers also
found that 50% more patients on
insulin glargine achieved HbA1c (68 vs. 42%) and compared to sitagliptin (p for both), which, according to the
study, indicates improved glycemic
control for a greater number of
insulin glargine patients.
“The findings of this study
comparing insulin glargine with
sitagliptin provide evidence to
support the recent ADA-EASD
proposal to consider early basal
insulin therapy as add-on to
metformin to help achieve glycemic
control in people with type 2
diabetes,” said principal
investigator Pablo Aschner,
Pontificia Universidad Javeriana,
Hospital Universitario San Ignacio,
Colombia.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jun 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jun 12
